Teleflex (NYSE:TFX) Announces Earnings Results

Teleflex (NYSE:TFX) posted its quarterly earnings results on Thursday. The medical technology company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.29, Zacks reports. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The company had revenue of $892.90 million for the quarter, compared to analysts’ expectations of $892.79 million. During the same period last year, the firm earned $3.49 earnings per share. Teleflex’s quarterly revenue was up 19.4% on a year-over-year basis. Teleflex updated its FY 2025 guidance to 14.000-14.200 EPS.

Teleflex Stock Performance

TFX traded down $16.25 during trading on Thursday, reaching $108.50. The company’s stock had a trading volume of 2,953,542 shares, compared to its average volume of 743,018. Teleflex has a 52-week low of $102.58 and a 52-week high of $203.33. The company’s fifty day moving average price is $126.01 and its 200-day moving average price is $123.27. The company has a market capitalization of $4.79 billion, a price-to-earnings ratio of 25.53, a price-to-earnings-growth ratio of 1.79 and a beta of 1.05. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.44 and a current ratio of 2.41.

Teleflex Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Friday, November 14th. Teleflex’s payout ratio is currently 32.00%.

Institutional Investors Weigh In On Teleflex

A number of institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. boosted its holdings in Teleflex by 17.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock valued at $148,000 after purchasing an additional 186 shares in the last quarter. State of Wyoming purchased a new stake in Teleflex in the 2nd quarter valued at approximately $111,000. Public Sector Pension Investment Board boosted its stake in shares of Teleflex by 2.3% during the 2nd quarter. Public Sector Pension Investment Board now owns 150,669 shares of the medical technology company’s stock worth $17,833,000 after acquiring an additional 3,371 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Teleflex during the 2nd quarter worth approximately $538,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Teleflex by 211.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,110 shares of the medical technology company’s stock worth $131,000 after acquiring an additional 754 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Analyst Upgrades and Downgrades

TFX has been the topic of a number of research analyst reports. Wells Fargo & Company cut their target price on Teleflex from $137.00 to $131.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Wall Street Zen cut Teleflex from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 15th. Zacks Research cut Teleflex from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Royal Bank Of Canada lifted their target price on Teleflex from $130.00 to $135.00 and gave the stock a “sector perform” rating in a research report on Friday, August 1st. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Teleflex in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $141.57.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.